van Haaften C, et al. - The goal of this research was to study additional therapeutic regimens. A better comprehension of the cellular and molecular mechanisms of the tumors in in-vitro models is important. It was concluded that the three new isogenic ovarian cancer cell lines were developed from a patient with a germline BRCA1 mutation. Chemosensitivity profiling of the cell lines exhibited a high tolerance for olaparib. Treatment with eremophila-1-(10)-11(13)-dien-12,8β-olide (EPD) proved synergistic with cisplatin. The impacts of EPD will be further examined for future clinical effectiveness.